{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:44:40Z","timestamp":1782254680530,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R03CA173834-02"],"award-info":[{"award-number":["1R03CA173834-02"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["2P30CA006516-47"],"award-info":[{"award-number":["2P30CA006516-47"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s10549-016-3686-2","type":"journal-article","created":{"date-parts":[[2016,1,19]],"date-time":"2016-01-19T12:08:06Z","timestamp":1453205286000},"page":"375-383","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A two-stage approach to genetic risk assessment in primary care"],"prefix":"10.1007","volume":"155","author":[{"given":"Swati","family":"Biswas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philamer","family":"Atienza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Chipman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.","family":"Blackford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banu","family":"Arun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Parmigiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,19]]},"reference":[{"key":"3686_CR1","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117\u20131130","journal-title":"Am J Hum Genet"},{"key":"3686_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.1088759","volume":"302","author":"MC King","year":"2003","unstructured":"King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643\u2013646","journal-title":"Science"},{"key":"3686_CR3","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1245\/s10434-012-2257-y","volume":"19","author":"B Drohan","year":"2012","unstructured":"Drohan B, Roche CA, Cusack JC (2012) Hughes KS (2012) Hereditary breast and ovarian cancer and other hereditary syndromes: using technology to identify carriers. Ann Surg Oncol 19:1732\u20131737","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 1","key":"3686_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1524-4741.2009.00796.x","volume":"15","author":"B Drohan","year":"2009","unstructured":"Drohan B, Ozanne EM, Hughes KS (2009) Electronic health records and the management of women at high risk of hereditary breast and ovarian cancer. Breast J 15(Suppl 1):46\u201355","journal-title":"Breast J"},{"key":"3686_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1086\/301670","volume":"62","author":"G Parmigiani","year":"1998","unstructured":"Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer- susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145\u2013158","journal-title":"Am J Hum Genet"},{"key":"3686_CR6","doi-asserted-by":"crossref","unstructured":"Chen S, Wang W, Broman KW, Katki HA, Parmigiani G (2004). BayesMendel: an R environment for Mendelian risk prediction. Stat Appl Genet Mol Biol 3(1):1\u201319; Article 21","DOI":"10.2202\/1544-6115.1063"},{"key":"3686_CR7","unstructured":"CancerGene (2015) \n                    https:\/\/www4.utsouthwestern.edu\/breasthealth\/cagene\/\n                    \n                  . Accessed 31 December 2015"},{"key":"3686_CR8","unstructured":"BayesMendel Web-based Risk Service (2015) \n                    http:\/\/bayesmendel.dfci.harvard.edu\/risk\/\n                    \n                  . Accessed 31 December 2015"},{"key":"3686_CR9","unstructured":"HughesRiskApps (2015) \n                    http:\/\/www.HughesRiskApps.com\n                    \n                  . Accessed 31 December 2015"},{"key":"3686_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/bcr1866","volume":"10","author":"YC Tai","year":"2008","unstructured":"Tai YC, Chen S, Parmigiani G, Klein AP (2008) Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction. Breast Cancer Res 10:401","journal-title":"Breast Cancer Res"},{"key":"3686_CR11","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1002\/sim.3302","volume":"27","author":"HA Katki","year":"2008","unstructured":"Katki HA, Blackford A, Chen S, Parmigiani G (2008) Multiple diseases in carrier probability estimation: accounting for surviving all cancers other than breast and ovary in BRCAPRO. Stat Med 27:4532\u20134548","journal-title":"Stat Med"},{"key":"3686_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2350-8-13","volume":"8","author":"HA Katki","year":"2007","unstructured":"Katki HA (2007) Incorporating medical interventions into Mendelian mutation prediction models. BMC Med Genet 8:13","journal-title":"BMC Med Genet"},{"key":"3686_CR13","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1200\/JCO.2008.20.6896","volume":"27","author":"S Chen","year":"2009","unstructured":"Chen S, Blackford A, Parmigiani G (2009) Tailoring BRCAPRO to Asian-Americans. J Clin Oncol 27:642\u2013643","journal-title":"J Clin Oncol"},{"key":"3686_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10549-012-1958-z","volume":"133","author":"S Biswas","year":"2012","unstructured":"Biswas S, Tankhiwale N, Blackford A, Barrera AM, Ready K, Lu K et al (2012) Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO. Breast Cancer Res Treat 133:347\u2013355","journal-title":"Breast Cancer Res Treat"},{"issue":"S2","key":"3686_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.4137\/CIN.S17292","volume":"14","author":"E Mazzola","year":"2015","unstructured":"Mazzola E, Blackford A, Parmigiani G, Biswas S (2015) Recent Enhancements to the genetic risk prediction model BRCAPRO. Cancer Inform 14(S2):147\u2013157","journal-title":"Cancer Inform"},{"key":"3686_CR16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10549-013-2564-4","volume":"139","author":"S Biswas","year":"2013","unstructured":"Biswas S, Atienza P, Chipman J, Hughes K, Gutierrez Barrera AM, Amos CI et al (2013) Simplifying clinical use of the genetic risk prediction model BRCAPRO. Breast Cancer Res Treat 139:571\u2013579","journal-title":"Breast Cancer Res Treat"},{"key":"3686_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1524-4741.2009.00690.x","volume":"15","author":"EM Ozanne","year":"2009","unstructured":"Ozanne EM, Loberg A, Hughes S, Lawrence C, Drohan B, Semine A et al (2009) Identification and management of women at high risk for hereditary breast\/ovarian cancer syndrome. Breast J 15:155\u2013162","journal-title":"Breast J"},{"key":"3686_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.7326\/0003-4819-147-7-200710020-00002","volume":"147","author":"G Parmigiani","year":"2007","unstructured":"Parmigiani G, Chen S, Iversen ES, Friebel TM, Finkelstein DM, Anton-Culver H et al (2007) Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med 147:441\u2013450","journal-title":"Ann Intern Med"},{"key":"3686_CR19","unstructured":"NCCN guidelines (2015) \n                    http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#detection\n                    \n                  . Accessed 31 December 2015"},{"key":"3686_CR20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1034\/j.1399-0004.2000.580408.x","volume":"58","author":"CA Gilpin","year":"2000","unstructured":"Gilpin CA, Carson N, Hunter AG (2000) A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. Clin Genet 58:299\u2013308","journal-title":"Clin Genet"},{"key":"3686_CR21","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1200\/JCO.1996.14.5.1730","volume":"14","author":"American Society of Clinical Oncology","year":"1996","unstructured":"American Society of Clinical Oncology (1996) Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol 14:1730\u20131736","journal-title":"J Clin Oncol"},{"key":"3686_CR22","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1001\/jama.296.12.1479","volume":"296","author":"S Chen","year":"2006","unstructured":"Chen S, Wang W, Lee S, Nafa K, Lee J, Romans K et al (2006) Prediction of germline mutations and cancer risk in the Lynch syndrome. J Am Med Assoc 296:1479\u20131487","journal-title":"J Am Med Assoc"},{"key":"3686_CR23","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1200\/JCO.2006.09.2452","volume":"25","author":"W Wang","year":"2007","unstructured":"Wang W, Chen S, Brune KA, Hruban RH, Parmigiani G, Klein AP (2007) PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol 25:1417\u20131422","journal-title":"J Clin Oncol"},{"key":"3686_CR24","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/0008-5472.CAN-09-2653","volume":"70","author":"W Wang","year":"2010","unstructured":"Wang W, Niendorf KB, Patel D, Blackford A, Marroni F, Sober AJ et al (2010) Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPRO. Cancer Res 70:552\u2013559","journal-title":"Cancer Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-3686-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-016-3686-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-3686-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-016-3686-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T13:11:14Z","timestamp":1589721074000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-016-3686-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["3686"],"URL":"https:\/\/doi.org\/10.1007\/s10549-016-3686-2","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"7 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Kevin Hughes is a founder of and has a financial interest in Hughes Risk Apps (HRA), LLC. Dr. Hughes\u2019s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. Kevin Hughes has received honoraria from Myriad Genetics Speaker\u2019s Bureau and holds stock options in 5 AM solutions. GP is on the SAB of HRA and holds stock options in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}